Key insights
- BofA Securities upgraded Erasca (ERAS) to Neutral, citing positive early data for its pan-RAS drug ERAS-0015 and constructive KOL feedback. The upgrade reflects the stock's recent surge and acknowledges potential upside from ERAS-4001. While execution risks and profitability concerns remain, the company's progress in RAS-mutant cancers, including a collaboration with Merck for Keytruda, suggests potential for continued investor interest in the biotech sector.
Investing.com - BofA Securities upgraded Erasca Inc (NASDAQ:ERAS) to Neutral from Underperform on Wednesday and raised its price target to $16.00 from $9.00. The stock currently trades at $13.18, reflecting a remarkable 761% return over the past year, though InvestingPro data suggests the shares may be overvalued at current levels relative to its Fair Value estimate.
The firm said early pan-RAS activity for ERAS-0015 appears real and feedback from key opinion leaders has been constructive. The analyst noted the share move now better reflects known risks.
BofA said ERAS-4001 adds a second opportunity in the second half of 2026 and could be an upside driver if a broader therapeutic window is realized. The firm said merger and acquisition activity remains a possibility, though the number of RAS developers is growing.
The firm said the company has more to prove as a viable fast-follower, with clinical differentiation on safety and survival, pivotal path design and prioritized cancer types, and litigation risk remaining outstanding questions. According to InvestingPro Tips, analysts do not anticipate the company will be profitable this year, underscoring execution risks ahead. ERAS-0015 has shown enough activity across non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer to keep Erasca in the RAS conversation, BofA said.
The firm said colorectal cancer combinations and ERAS-4001 are the key near-term upside drivers, particularly if pan-KRAS can deliver similar efficacy with better tolerability than pan-RAS.
In other recent news, Erasca Inc. announced a clinical trial collaboration with Merck to evaluate a combination therapy for patients with RAS-mutant solid tumors. This collaboration will focus on the AURORAS-1 study, where Erasca’s investigational drug ERAS-0015 will be combined with Merck’s Keytruda. Erasca will sponsor the trial, while Merck will provide Keytruda at no cost. In related developments, H.C. Wainwright reiterated a Buy rating for Erasca, maintaining a $20 price target after preliminary Phase 1 data showed promising response rates for ERAS-0015 in lung cancer treatments. However, the company faced a setback as a patient died following severe side effects from its experimental treatment, resulting in a significant drop in its stock value. Additionally, Mizuho adjusted its price target for Erasca to $26 from $28, reflecting a $150 million payment to Joyo for rights to ERAS-0015. These developments highlight the dynamic nature of Erasca’s ongoing clinical efforts and partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.